跳至主要内容
临床试验/NCT07825818
NCT07825818招募中1 期

Imaging Mitochondrial Complex-I With [F-18]BCPP-EF Positron Emission Tomography (PET) in Alcohol Use Disorder (AUD)

Rajesh Narendran1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年9月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Dorsolateral prefrontal cortex [F-18]BCPP-EF VT

研究概览

简要总结

Studies proposed in this application will image mitochondrial Complex-I (MCI-I) and cerebral glucose metabolism (CGM) in alcohol use disorder (AUD) and matched healthy controls

详细描述

This study uses [18F]BCPP-EF and [18F]FDG positron emission tomography (PET) to image mitochondrial complex I and cerebral glucose metabolism (CGM) in subjects with alcohol use disorder (AUD) and healthy controls (HC). Correlating PET outcome measures with relapse to alcohol in this study will clarify the mechanisms by which abnormal brain energetics modulate addictive behaviors.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Alcohol use disorders (AUD)
  • Males or females between 18 and 55 years old
  • fulfill DSM-5 criteria for alcohol use disorder
  • History of NIAAA heavy drinking (for males, routinely consuming more than 4 drinks on any day or more than 14 drinks per week; for females, routinely consuming more than 3 drinks on any day or more than 7 drinks per week) in the past 30 days
  • No other major DSM-5 psychiatric disorders including schizophrenia, schizoaffective disorder, bipolar disorder, developmental disorders, or current depressive disorders (unless they are related to alcohol intoxication, withdrawal, or an alcohol- induced mood disorder).
  • No other DSM-5 substance use disorders including opioids, cocaine, amphetamines, sedative-hypnotics, hallucinogens, and inhalants. Subjects with moderate and severe DSM-5 cannabis and tobacco use disorder will also be excluded;
  • Subjects not currently on psychotropic or medical medications that can influence binding to MC-I (e.g., metformin) or CGM (e.g., insulin, GLP-1 agonists), or increase the risks associated with an arterial line (e.g., warfarin, clopidogrel, aspirin, naproxen, ibuprofen, etc.).
  • No medical disorders that can influence the PET outcome measures (for example, MC-I binding is altered in Parkinson's disease, mild or major neurocognitive disorders, and mitochondrial disorders; CGM is altered in diabetes, severe hyperlipidemia, hypertension, obesity), increase the risks associated with blood sampling (anemia), or placement of an arterial line (history of deep vein thrombosis, pulmonary embolism, thrombocytopenia or thrombocytosis) for PET
  • Not currently pregnant or breast-feeding
  • Not currently employed as a radiation worker; or has participated in a radiation-related research protocol within the previous year such that the total cumulative annual radiation dose (i.e., from participation in the previous radioactive drug study [studies] and this study) would exceed the radiation dose limits specified in the FDA regulations (i.e., 21 CFR 361.1) that govern the research use of radiotracers
  • No medical or psychiatric contraindications to undergo an MRI scan (such as ferromagnetic tattoos/piercings, implants, medical equipment, history of gunshot, and claustrophobia).
  • Healthy controls (HC)
  • Males or females between 18 and 55 years old
  • No current or past DSM-5 psychiatric or substance use disorders other than tobacco use disorder
  • No history of heavy drinking as defined using NIAAA criteria in the past year
  • 5 to 10 above.

排除标准

  • 未提供

研究组 & 干预措施

PET

Experimental

Positron Emission Tomography Scans

干预措施: [F-18]BCPP-EF (Drug)

PET

Experimental

Positron Emission Tomography Scans

干预措施: [F-18]FDG (Drug)

结局指标

主要结局

Dorsolateral prefrontal cortex [F-18]BCPP-EF VT

时间窗: Baseline scan (time 0)

VT is the volume of distribution expressed relative to total plasma radioligand concentration, mL/cm3

Orbitofrontal cortex [F-18]BCPP-EF VT

时间窗: Baseline scan (time 0)

VT is the volume of distribution expressed relative to total plasma radioligand concentration in mL/cm3

Medial Prefrontal Cortex [F-18]BCPP-EF VT

时间窗: Baseline scan (time 0)

VT is the volume of distribution expressed relative to total plasma radioligand concentration, mL/cm3

Dorsolateral prefrontal cortex [F-18]FDG SUVR

时间窗: Baseline scan (time 0)

SUVR is the standardized uptake value ratio with whole brain activity as a reference region, unitless

Orbitofrontal cortex [F-18]FDG SUVR

时间窗: Baseline scan (time 0)

SUVR is the standardized uptake value ratio with whole brain activity as a reference region, unitless

Medial Prefrontal Cortex [F-18]FDG SUVR

时间窗: Baseline scan (time 0)

SUVR is the standardized uptake value ratio with whole brain activity as a reference region, unitless

次要结局

  • Relapse to alcohol severity measure(during 8-week follow up)
  • Penn Alcohol Craving Scale (PACS)(during 8-week follow up)

研究者

发起方
Rajesh Narendran
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Rajesh Narendran

Professor of Radiology and Psychiatry

University of Pittsburgh

研究点 (1)

Loading locations...

相似试验